These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25040021)

  • 1. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.
    Clark RE; Baxter JD; Barton BA; Aweh G; O'Connell E; Fisher WH
    Health Serv Res; 2014 Dec; 49(6):1964-79. PubMed ID: 25040021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
    Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
    J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.
    Asche CV; Clay E; Kharitonova E; Zah V; Ruby J; Aballéa S
    J Med Econ; 2015; 18(8):600-11. PubMed ID: 25851505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
    Kaur AD; McQueen A; Jan S
    J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?
    Clark RE; Baxter JD
    JAMA Intern Med; 2013 Sep; 173(17):1571-2. PubMed ID: 23877740
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.
    Mark TL; Parish WJ; Zarkin GA
    JAMA Netw Open; 2020 Apr; 3(4):e203132. PubMed ID: 32310285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.
    Clark RE; Samnaliev M; Baxter JD; Leung GY
    Health Aff (Millwood); 2011 Aug; 30(8):1425-33. PubMed ID: 21821560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of an opioid management initiative by a state Medicaid program.
    Garcia MM; Angelini MC; Thomas T; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2014 May; 20(5):447-54. PubMed ID: 24761816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Linas BP; Walley AY; LaRochelle MR
    Med Care; 2022 Mar; 60(3):256-263. PubMed ID: 35026792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
    Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
    J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018.
    Barenie RE; Sinha MS; Kesselheim AS
    Value Health; 2021 Feb; 24(2):182-187. PubMed ID: 33518024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
    Knudsen HK; Studts JL
    J Behav Health Serv Res; 2019 Jan; 46(1):151-163. PubMed ID: 30069622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.
    Landis RK; Opper I; Saloner B; Gordon AJ; Leslie DL; Sorbero M; Stein BD
    Drug Alcohol Depend; 2022 Dec; 241():109669. PubMed ID: 36332589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
    Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
    J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world changes in US health system hospital-based services following treatment with a prescription digital therapeutic for opioid use disorder.
    Velez FF; Colman S; Kauffman L; Anastassopoulos K; Murphy S; Maricich Y
    Hosp Pract (1995); 2021 Dec; 49(5):341-347. PubMed ID: 34275401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.
    Baxter JD; Clark RE; Samnaliev M; Aweh G; O'Connell E
    Subst Abus; 2015; 36(2):174-82. PubMed ID: 25706332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.